Patents by Inventor ERIC ESCOBAR CABRERA

ERIC ESCOBAR CABRERA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210371530
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 2, 2021
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
  • Publication number: 20210363256
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: July 23, 2021
    Publication date: November 25, 2021
    Inventors: Laurence FAYADAT-DILMAN, Veronica JUAN, Shireen KHAN, Shaopeng HUANG, Hua YING, Eric Escobar CABRERA, Genevieve DESJARDINS
  • Patent number: 11072658
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 27, 2021
    Assignees: MERCK SHARP & DOHME CORP., ZYMEWORKS, INC.
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
  • Publication number: 20190233518
    Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 1, 2019
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying, Eric Escobar Cabrera, Genevieve Desjardins
  • Patent number: 9562109
    Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 7, 2017
    Assignee: Zymeworks Inc.
    Inventors: Thomas Spreter Von Kreudenstein, Eric Escobar Cabrera, Surjit Bhimarao Dixit, Paula Irene Lario, David Kai Yuen Poon
  • Publication number: 20120149876
    Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
    Type: Application
    Filed: November 4, 2011
    Publication date: June 14, 2012
    Applicant: ZYMEWORKS INC.
    Inventors: THOMAS SPRETER VON KREUDENSTEIN, ERIC ESCOBAR CABRERA, SURJIT BHIMARAO DIXIT, PAULA IRENE LARIO, DAVID KAI YUEN POON, IGOR EDMONDO PAOLO D'ANGELO